No Data
No Data
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using target
Earnings Call Summary | Kymera Therapeutics(KYMR.US) Q1 2024 Earnings Conference
The following is a summary of the Kymera Therapeutics, Inc. (KYMR) Q1 2024 Earnings Call Transcript:Financial Performance:Kymera reported Q1 2024 revenue of $10.3 million, solely from its collaboratio
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript
Companies Like Kymera Therapeutics (NASDAQ:KYMR) Can Afford To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.com
Kymera Therapeutics Is Maintained at Outperform by Oppenheimer
Kymera Therapeutics Is Maintained at Outperform by Oppenheimer
Oppenheimer Keeps Their Buy Rating on Kymera Therapeutics (KYMR)
No Data